AMGN options sentiment shifts further as earnings approach

Amgen has extended its rally to 6.3% on the week, closing at $438.94, yet the options market has quietly moved to its most call-heavy reading in months, a notable shift for a stock that spent most of September weighted toward downside protection.

The options signal is the sharpest data point this week. The put/call ratio dropped to 0.953 on Tuesday, more than two standard deviations below its 20-day mean of 1.06. For context, Amgen's PCR sat above 1.0 every single day from early September through mid-October, so the move to sub-1.0 territory is a genuine break from an extended run of hedged positioning. The 52-week range stretches from 0.62 to 1.38, and the current reading is now closer to the bullish end of that band than it has been since before the summer. The borrow market reinforces the picture of a stock with little active short pressure: availability is essentially uncapped at 9,999%, and cost to borrow sits at just 0.40%, well below the brief spike toward 0.59% seen earlier in the week. Short interest has also eased, down 3.2% over the past week to 2.4% of the free float, a level too low to be a meaningful overhang.

The Street's posture is more divided than the tape suggests. Analyst activity over the past two weeks has split in opposite directions. Barclays raised its target to $400 from $380 this morning while holding an Equal-Weight rating. UBS and RBC lifted their targets to $470 and $430 respectively in early October, both with positive ratings. Set against that, Morgan Stanley, BMO Capital, Wells Fargo and Guggenheim all trimmed targets over the same period, none changing their neutral-to-hold ratings. The consensus mean target works out to roughly $396, below Tuesday's close of $438.94, which means a majority of the Street is technically rating the stock below where it now trades. The bull case centres on six key growth products that expanded 26% year on year in Q2 and the survival-benefit data from Imdelltra's Phase 3 trial. The bear case points to Q3 revenue and EPS estimates running below consensus, with pressure on Prolia, Otezla and Xgeva alongside the failed pelacarsen endpoint narrowing the Lp(a) pipeline story.

Amgen's closest biotech peers moved broadly in line this week. REGN gained 7.2%, INCY rose 7.4%, VRTX added 6.1% and ABBV was up 5.4%. HALO outpaced the group at 13.5%. Amgen's 6.3% gain puts it squarely in the middle of the pack, neither lagging nor leading. That kind of sector-wide move complicates the signal from the options shift: it is harder to read the call rotation as Amgen-specific conviction when the whole group is repricing.

One macro-level data point deserves mention. Medicaid units reimbursed for Amgen drugs fell 24% against the same period a year earlier in Q1 2026, with Medicaid prescriptions down 23% year on year over the same period. These are public reimbursement figures from the Centers for Medicare & Medicaid Services, not a forward indicator, but the scale of the decline is worth carrying into any read on volume trends heading into the November 3 earnings date.

The next concrete test is that Q3 report on November 3, where the tension between the improving options sentiment and the cautious analyst target-price cluster will either resolve or widen further.